Ignite Creation Date:
2024-05-05 @ 5:27 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00452491
Status:
COMPLETED
Last Update Posted:
2010-10-05
First Post:
2007-03-23
Brief Title:
MAXOMAT in the Treatment of Severe Early Onset Intrauterine Growth Retardation on Pre-pubertal Children
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
A Cohort of Pre-pubertal Children for the Study of Optimization of Methods of Administration of the Biosynthetic Growth Hormone MAXOMAT in the Treatment of Severe Early Onset Intrauterine Growth Retardation
Status:
COMPLETED
Status Verified Date:
2010-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
1 To test for equivalence in terms of catch-up growth between the 2 therapeutic regimens
2 To specify the best period of treatment
3 To assess the efficacy of treatment based on final adult height of these children
2 To specify the best period of treatment
3 To assess the efficacy of treatment based on final adult height of these children
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None